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Abstract 
Genome-wide association studies (GWAS) have identified thousands of variants 
robustly associated with complex traits. However, the biological mechanisms underlying 
these associations are, in general, not well understood. We propose a gene-based 
association method called PrediXcan that directly tests the molecular mechanisms 
through which genetic variation affects phenotype. The approach estimates the 
component of gene expression determined by an individual’s genetic profile and 
correlates the “imputed” gene expression with the phenotype under investigation to 
identify genes involved in the etiology of the phenotype. The genetically regulated gene 
expression is estimated using whole-genome tissue-dependent prediction models 
trained with reference transcriptome datasets. PrediXcan enjoys the benefits of gene-
based approaches such as reduced multiple testing burden and a principled approach 
to the design of follow-up experiments. Our results demonstrate that PrediXcan can 
detect known and novel genes associated with disease traits and provide insights into 
the mechanism of these associations. 
 
Introduction 
Genome-wide association studies (GWAS) have been remarkably successful in 
identifying susceptibility loci for complex diseases. These studies typically conduct 
single-variant tests of association to interrogate the genome in an agnostic fashion and, 
due to modest effect sizes, have come to rely on ever-greater sample sizes1,2 to make 
meaningful inferences. We have been less successful in developing methods that 
improve on existing simple approaches. In general, the genetic associations identified 
as genome-wide significant thus far account for only a modest proportion of variance in 
disease risk3. Indeed, there is now widespread recognition, if not consensus, that 
GWAS of disease susceptibility (for which, the relevant genetic effects may be very 
small) and pharmacologic traits (for which large effect sizes are not unusual)4,5 have 
resulted in limited conclusive findings on the genetic factors contributing to complex 
traits. Importantly, the functional significance of most discovered loci, including even 
those that have been the most reproducibly associated, remains unclear. Assigning a 
causal link to the nearest gene falls short of elucidating a functional connection, as 
recently demonstrated by the obesity-associated variants within FTO that form long-
range functional connections with IRX36. And while GWAS will no doubt continue to 
identify many more susceptibility loci, the question of how to advance biological 
knowledge of the underlying mechanisms of disease risk remains a paramount 
challenge. 
A large portion of phenotypic variability in disease risk for a broad spectrum of 
disease phenotypes can be explained by regulatory variants, i.e. genetic variants that 
regulate the expression levels of genes7-10. For example, almost 80% of the chip-based 
heritability of disease risk for 11 diseases from the WTCCC can be explained by 
genome variation in DNase I hypersensitivity sites, which are likely to regulate 
chromatin accessibility and thus transcription11. 
Large genomic consortia (e.g., ENCODE12) are generating an unprecedented 
volume of data on the function of genetic variation. The Genotype-Tissue Expression 
(GTEx13) project is an NIH Common Fund project that aims to collect a comprehensive 
set of tissues from 900 deceased donors (for a total of about 20,000 samples) and to 
provide the scientific community a database of genetic associations with molecular traits 
such as mRNA levels. (See GTEx main paper14 on Phase 1 data.) Other large-scale 
transcriptome datasets include Genetic European Variation in Health and Disease15 
(GEUVADIS, 460 lymphoblastoid cell lines), Depression Genes and Networks (DGN, 
922 whole blood samples)16, and Braineac (130 individuals with multiple brain region 
samples)17. Yet, effective methods that harness these reference transcriptome datasets 
for disease mapping are lacking.  
Methodologically, gene-based approaches and multi-marker association tests 
have been developed as alternatives to traditional single-variant tests. By conducting 
tests of association on biologically informed aggregates of SNPs, such tests seek to 
evaluate a priori functionally relevant units of the genome and, in many cases, reduce 
the multiple-testing penalty that plague single-variant approaches, by 10 to 100 fold. 
The incorporation of -omics data, such as those being generated by high-resolution 
transcriptome studies, provides a means to extend genome-wide association studies by 
addressing the functional gap. Technological advances in high-throughput methods 
have reinforced the important finding that intermediate molecular phenotypes are under 
significant genetic regulation, with expression quantitative trait loci (eQTLs) as the 
predominant example. However, approaches that fully leverage the comprehensive 
regulatory knowledge generated by transcriptome studies are relatively lacking despite 
the fact that these studies have the potential to dramatically improve our understanding 
of the genetic basis of complex traits13.  
We hypothesized that a SNP aggregation approach that integrates information 
on whether a SNP regulates the expression of a gene can greatly increase the power to 
identify trait-associated loci either from a strong functional SNP signal or from a 
combination of modest signals, the so-called grey area of GWAS. The present study 
suggests that PrediXcan, a novel method that incorporates information on gene 
regulation from a set of markers, increases the power to detect associations relative to 
traditional SNP-based GWAS and known gene-based tests under a broad range of 
genetic architectures and provides mechanistic insights and more easily interpreted 
direction of effect into the observed associations.  
 
Results 
PrediXcan method 
 PrediXcan, by design, exploits genetic control of phenotype through the 
mechanism of gene regulation as a way to identify trait-associated genes. Figure 1 is a 
schematic diagram of the regulatory mechanism that is tested with PrediXcan. An 
individual's gene expression level (typically unobserved in a GWAS) is decomposed into 
a genetically regulated expression (GReX) component, a component altered by the trait 
itself (i.e., a reverse causal effect that may occur if disease status or other conditions 
alter expression levels), and the remaining component attributable to environmental and 
other factors. PrediXcan tests the mediating effect of gene expression by quantifying the 
association between GReX and the phenotype of interest. 
 We use reference transcriptome datasets from studies such as GTEx13, 
GEUVADIS15, and DGN16 among others, to train additive models of gene expression 
levels. These models allow us to estimate the genetically regulated expression, GReX. 
We denote the estimated value with a hat, ܩܴ݁෣ܺ . These estimates constitute multiple-
SNP prediction of expression levels. The weights for the estimation are stored in our 
publicly available database. 
 The analogy with genotype imputation is relevant here. Genotype imputation 
uses information from a reference sample to learn how to impute genotypes at the 
unmeasured SNPs in the test set. Similarly, PrediXcan uses a reference dataset in 
which both genome variation and gene expression levels have been measured to 
develop prediction models for gene expression. We use these prediction models to 
“impute” gene expression (which is unobserved in a typical GWAS), and we do so by 
estimating the genetically determined component, GReX. 
PrediXcan application to a GWAS dataset consists of “imputing” the 
transcriptome using the weights derived from reference transcriptome datasets and 
correlating the GReX with the phenotype of interest using regression methods (e.g., 
linear, logistic, Cox) or non-parametric approaches (e.g., Spearman). (For the specific 
results on disease phenotypes analyzed here, we used logistic regression with disease 
status.) We are aware of the attenuation bias that arises because of the error in the 
estimation of GReX. This is a subject to be investigated in the future, but this bias does 
not invalidate our analysis since we only use the estimate of GReX as a discovery tool.  
Figure 2 summarizes the flow of the method development described above. 
Features of PrediXcan 
PrediXcan is, as we have emphasized, particularly focused on a mechanism – gene 
expression regulation – that has already been established as being contributory to 
common diseases, including psychiatric and neurodevelopmental disorders7. The test 
has the potential to identify gene targets for therapeutic applications because it is 
inherently mechanism-based and provides directionality.  
Additional advantages include: 
• Like other gene-based tests, it has much smaller multiple-testing burden (~20K 
tests maximum, ~10K genes with high quality prediction in most tissues) compared 
to single variant tests (~5–10M tests). Moving beyond the stringent Bonferroni 
correction, priors on genes can be less restrictive than for SNPs. 
• Informative priors and groupings of functional units (based on known pathways, for 
example) are much more straightforward to construct for genes than SNPs. 
• No actual transcriptome data are required since the predicted expression levels 
are a function of genetic variation alone. Thus, the method can be applied to any 
existing dataset with large-scale genome interrogation such as those in dbGaP or 
other repositories. Re-analyses of existing datasets, with a focus on mechanism 
using PrediXcan, address a gap that has largely characterized GWAS to date.  
• Reverse causality is not a major concern since disease status or drug treatment 
does not alter germline genomic variation. 
• Meta-analysis of gene-based results is simplified since less stringent 
harmonization between studies is required. 
• Multiple tissues can be evaluated using a reference transcriptome dataset (such as 
GTEx). In general, the only limitation is the availability of gene expression data in 
the given tissue for model building, which need not be, from the same study as that 
used for phenotype investigation. In cases where transcriptome data are available, 
separate analyses should be performed to simplify interpretation.  
• The approach can be applied to common or rare variants. In general, larger 
sample sizes for the training set will be needed to achieve good prediction models 
with rare variants. 
Database of prediction models and software 
We make the prediction models (derived from LASSO18 and elastic net19) and the 
software to predict the transcriptome (in a variety of tissues) (see Materials and 
Methods) publicly available.   
Predicting the transcriptome 
We built prediction models in the DGN whole blood cohort using LASSO, the 
elastic net (⍺=0.5), and polygenic score at several p-value thresholds (single top SNP, 
1x10–4, 0.001, 0.01, 0.05, 0.5, 1). We assessed predictive performance using 10-fold 
cross-validation (R2 of estimated GReX vs. observed expression) as well as in an 
independent set. We found that LASSO performed similarly to the elastic net and that 
LASSO outperformed the polygenic score at all thresholds, although all methods are 
highly correlated (see Supplemental Figure 1). For subsequent analyses, we focused on 
the prediction models using the elastic net because we found it to perform well and to 
be more robust to slight changes in input SNPs (potentially due to variations in 
imputation quality between cohorts).  
We estimated the heritability of gene expression in DGN attributable to SNPs in 
the vicinity of each gene using a mixed-effects model (see Materials and Methods) and 
calculated variances using restricted maximum likelihood as implemented in GCTA20. 
We use only local SNPs since we found that heritability estimates using all genotyped 
SNPs were too noisy to make meaningful inferences. 
We use heritability estimates as our benchmark for the prediction R2 since this 
constitutes the upper limit of our prediction performance. For genes for which an elastic 
net model was available (n=10,427), the average heritability in DGN was 0.153. In 
comparison, the average 10-fold cross-validated prediction R2 for elastic net was quite 
close at 0.137; for the polygenic score (P<1x10–4) and top-SNP models, average 
prediction R2 values were sizably lower at 0.099 and 0.114, respectively. We show the 
performance R2 for each model in Figure 3, with the corresponding heritability estimate 
and confidence interval in the background for comparison. We also note that elastic net 
predictive performance reached or exceeded the lower bound of the heritability estimate 
for 94% of genes, while polygenic score (P<1x10–4) did so for just 76% of the genes and 
the top SNP for 80% of the genes (Figure 3), consistent with the performance ranking 
given by the average (across genes) R2. 
 Predictive performance of elastic net was similar whether all SNPs from the 1000 
Genomes imputation or the HapMap Phase II subset were included in the model 
building (Supplemental Figure 2). Models based on imputed data (both the 1000 
Genomes and the HapMap subset) substantially outperformed models based on 
genotyped SNPs in WTCCC (Supplemental Figure 2). Thus, we chose the elastic net 
models built in the smaller HapMap SNP subset, relative to 1000 Genomes, in our 
applications of PrediXcan to reduce computation time without sacrificing performance. 
As reference transcriptome studies increase in sample size, we may need to switch to a 
more dense imputation to take advantage of increased prediction performance from rare 
variants. 
We also tested the prediction models trained in the DGN whole blood cohort on 
several independent test cohorts with available whole-genome genotype and 
transcriptome data. We used weights derived from the DGN whole blood data (“training 
set”) to predict gene expression levels (treated as quantitative traits) in GEUVADIS 
LCLs (lymphoblastoid cell lines) and nine GTEx pilot tissues (“test sets”). Figure 4 
provides a Q-Q plot showing the expected (under the null, correlation between two 
independent vectors with the same sample size) and observed R2 (between observed 
and predicted) from the elastic net prediction in GEUVADIS LCLs. We find a substantial 
departure from the null distribution indicating that the elastic net model trained in DGN 
(equation 2 of Materials and Methods, with effect size estimates ݓෝ௞,௚ாே) captures a 
significant proportion of the transcriptome variability. The average prediction R2 is 
0.0197 for GEUVADIS LCLs. For GTEx tissues, the prediction R2 values are 0.0367 
(adipose), 0.0358 (tibial artery), 0.0356 (left ventricular heart), 0.0359 (lung), 0.0269 
(muscle), 0.0422 (tibial nerve), 0.0374 (sun exposed skin), 0.0398 (thyroid), and 0.0458 
(whole blood). Interestingly, we also find a substantial departure from the null 
distribution of expected R2 values for predicted expression using DGN weights in each 
of the nine GTEx tissues suggesting that models developed in whole blood are still 
useful for understanding diseases that affect other primary tissues (Supplemental 
Figure 3). Consistent with this, average prediction R2 is highest for whole blood as 
expected but the loss in power for other tissues is modest. 
Figure 5 illustrates the genes with some of the highest correlations from this 
analysis, providing a comparison of the predicted expression and the observed 
expression. Among these genes, both ERAP2 and its paralog ERAP1 play fundamental 
roles in MHC antigen presentation21, immune activation and inflammation.  
We also generated prediction models trained in the DGN whole blood cohort that 
included trans-eQTLs (>1Mb from gene start or end or on a different chromosome) 
generated from linear regression (p<10–5).  We tested the predictive performance of 
these models in the GTEx whole blood cohort. While a few genes had higher 
correlations between predicted and observed expression than expected by chance, the 
departure from the null distribution was much smaller than that for the prediction models 
based on local SNPs (Supplemental Figure 4), perhaps due to the low power to map 
trans SNPs. Based on this result, in this paper we focus primarily on results based on 
local SNPs. 
Application of PrediXcan to WTCCC  
 We applied PrediXcan to seven complex disease phenotypes from the WTCCC 
study22. For this purpose, we utilized the DGN whole blood elastic net prediction 
models.  We correlated the estimated genetically regulated gene expression for close to 
8700 genes with disease status for each WTCCC dataset and identified 41 significant 
associations (Bonferroni corrected p < 0.05) with five diseases (Table 1). Notably, we 
identified 29 genes associated with type 1 diabetes (T1D) risk (Table 1 and Fig. 6), 8 of 
which were outside of the extended MHC.  Complete results for the remaining 6 
diseases are shown in Supplemental Figures 5 and 6. Consistent with the original 
GWAS of WTCCC diseases, our most significant results were for autoimmune 
diseases22.  
  As has been previously reported for complex autoimmune diseases23, we 
observed genes that were associated with multiple autoimmune diseases, namely T1D, 
Crohn’s disease (CD), and rheumatoid arthritis (RA). Interestingly, the top (genome-
wide significant) PrediXcan gene for both T1D and RA, DCLRE1B, has not been 
previously reported (in the NHGRI catalog) in either disease, but has been linked to CD, 
ulcerative colitis and inflammatory bowel disease24. Lower predicted expression of 
DCLRE1B was associated with increased disease risk for both RA and T1D. 
Interestingly, higher predicted expression of DCLRE1B was nominally associated with 
increased Crohn’s disease risk in our PrediXcan analysis (p = 0.001).  Similarly, 
PTPN22 was significantly (positively) associated with RA and T1D (table 1), and 
nominally (negatively) associated with CD (p-value = 0.017). Previous single variant 
analyses implicated PTPN22 with multiple autoimmune diseases including RA, T1D, 
CD, myasthenia gravis, and vitiligo according to the NHGRI catalog25. These results 
highlight the known overlap in genetic risk factors for autoimmune diseases.  
All genes in table 1, excluding PTPRE and KCNN4 (discussed below), have been 
either previously reported with GWAS studies, or are located in the vicinity of reported 
genes (within 1MB). About 35% of all GENCODE protein-coding genes are reported (in 
the NHGRI catalog) or within 1 MB of a reported gene as associated with a WTCCC 
disease.  For T1D, 5 out of the 29 genome-wide significant genes have been reported 
via conventional single variant analyses (as curated by the NHGRI25 repository of 
GWAS results). Furthermore, 21 of the genes associated with T1D in our analysis lie 
within the extended MHC (Table 1), a region that is known to be associated with 
disease risk26. Additionally, ERBB3, which contains SNPs previously associated with 
T1D in GWAS27, showed a negative correlation with disease risk in PrediXcan (p < 10–
11), which is consistent with a prior study that showed risk genotypes associated with 
lower expression of ERBB3 in PBMCs28. Furthermore, it has been reported that 
subjects with protective genotypes had higher percentages of ERBB3+ monocytes and 
dendritic cells leading to greater T cell proliferation28. These results highlight one of the 
key advantages of PrediXcan, which is to provide the direction of effect. 
The results described above highlight gene associations that attain genome-wide 
significance. Additionally, we tested for enrichment of reported disease genes among 
our PrediXcan results using less stringent significance thresholds. Reported genes were 
derived from the comprehensive NHGRI catalog of disease-associated variants 
identified using GWAS25. Five of the seven diseases (bipolar disorder (BD), coronary 
artery disease (CAD), CD, RA, T1D) had a significant enrichment of reported genes in 
the PrediXcan results (Figure 6C, Supplemental Figure 7). Results for other p-value 
thresholds were similar (results not shown).  These enrichment analyses on the 
PrediXcan findings suggest that among the genes that fail to meet strict genome-wide 
significance, there are likely to be true disease associations.  
In addition to the results described above for autoimmune diseases, we identified 
two potentially novel disease-associated genes. Lower predicted expression of KCNN4 
was associated with an increased risk of hypertension (p-value = 2.62 x 10–6, Table 1) 
and high predicted PTPRE expression was associated with increased risk of bipolar 
disorder (p-value = 7.71 x 10–7, Table 1). Interestingly, an intronic SNP in PTPRE was 
previously found to associate with response to the stimulant amphetamine29,30. In 
contrast to the original WTCCC single-variant analyses22, the PrediXcan analysis for 
bipolar disorder and hypertension produced genome-wide significant results. Additional 
studies of these genes are warranted.  
Using publically available meta-analysis results, we summarized the single-
variant association results for SNPs that are included in the prediction models for the 
top disease-associated PrediXcan genes. See Supplemental Note and Supplemental 
Table 1 for the results of this analysis.  
 We applied PrediXcan and two widely-used gene-based tests (VEGAS and 
SKAT) to WTCCC. In a Q-Q plot showing all three distributions of p-values, for genes 
outside of the HLA region, from these gene-based tests (Figure 7), SKAT had improved 
performance relative to VEGAS, and PrediXcan showed the most extreme departure 
from the null at the tail end of the distribution.  
 To replicate our findings, we applied the DGN elastic net whole blood prediction 
models to an independent rheumatoid arthritis GWAS from Vanderbilt University’s 
BioVU repository (see Materials and Methods).  Both genes (DCLRE1B and PTPN22) 
that were found to be genome-wide significant in the WTCCC rheumatoid arthritis data 
were also significant, with concordant direction of effect, in the replication samples (p = 
0.012 and p = 0.036, respectively). 
 
Discussion 
Gene expression, as an intermediate phenotype between genetic variation and 
higher-level phenotypes, is an important mechanism underlying disease susceptibility 
and drug response. Studies of the transcriptome in several tissues13 have shown that 
variation in gene expression is heritable32,33 and can be mapped to the genome. 
Particularly, eQTL mapping provides an immediate view of the effects of genetic 
variants on the phenotype closest to genetic variation, namely transcript abundance, 
and thus promises to enable the discovery of the molecular mechanisms underlying 
human phenotypic variation34. Furthermore, transcriptome regulation studies facilitate 
the consideration of thousands of gene expression phenotypes in parallel, thereby 
enabling a comprehensive approach to understanding the genetic basis of complex 
traits35. In this study, we developed a method that explicitly utilizes the wealth of 
regulatory information derived from transcriptome regulation studies to map trait-
associated loci. 
Our PrediXcan method tests the mediating effects of gene expression levels by 
quantifying the association between the genetically regulated levels of expression and 
the phenotype of interest. To implement this, we developed prediction models of gene 
expression using large-scale transcriptome study datasets (DGN, GEUVADIS, GTEx). 
(Summary statistics on samples per tissue for every data release are available from the 
GTEx portal.) After extensive testing, we chose to use the elastic net model, which 
performed similarly to LASSO, but substantially outperformed simple polygenic 
approaches. Manor and Segal36 have published results on robust prediction of 
expression levels using K nearest neighbor (KNN) and elastic net approaches. Based 
on their conclusion that a combination of elastic net and KNN along with the use of 
genomic annotation such as GC content can improve prediction performance, it is 
reasonable to hypothesize that the incorporation of a more comprehensive functional 
annotation approach into the PrediXcan framework can yield additional performance 
gain. 
Application of the method to WTCCC data recapitulated many known loci but 
also identified novel genome-wide significant genes. We believe that a systematic re-
analyses of GWAS datasets in comprehensive repositories such as dbGAP and the 
European Genome-phenome Archive (EGA) could provide a cost-effective approach to 
uncovering novel disease mechanisms using only existing genomic resources.  
In contrast to other gene-based tests, PrediXcan provides the direction of effect, 
which may yield opportunities for therapeutic development. The development of 
therapeutics that down-regulate a gene is generally easier to achieve than therapeutics 
that up-regulate a gene; thus, genes with expression levels that are positively correlated 
with disease risk may be more favorable drug targets for novel therapies. The direction 
of effect may also provide information to elucidate pathways and the opportunity to 
explore systems-based approaches to the development of disease. The prediction 
models can be applied to genotype data of subjects in large biobanks to investigate 
potential side-effects of drugs with specific gene targets. Finally, direction of effect can 
be used to improve the interpretation of sequence analyses of genes showing 
significant correlation of predicted expression with phenotype, since phenotypes 
associated with reduced expression of genes are more likely to show a relative excess 
of rare variants. Indeed, we believe that PrediXcan offers intriguing opportunities to 
combine results of rare and common variant association tests within whole genome 
sequencing studies, and more generally, to combine results of rare variant gene-based 
tests from sequencing studies with results of PrediXcan gene-based tests from the large 
body of existing GWAS for the same phenotypes. Thus, PrediXcan is a method 
developed to integrate –omics data that can facilitate integration of results from 
common and rare variant studies.  
Regarding the multiple testing correction approach, here we have used 
Bonferroni correction using the total number of genes tested. In general, both single-
variant and PrediXcan analyses will be performed; thus the question that arises is how 
to address the issue of multiple testing adjustment. The prior probability for a SNP to be 
causal is much smaller than the prior probability of causality for a gene so it would not 
be fair to subject SNP tests and gene-based tests to the same level of adjustment. 
Since we are presenting only gene-based results in our application and given the highly 
conservative nature of Bonferroni correction, there is no need to further adjust our 
results. A more conservative approach would be to divide the significance threshold 
used by a factor of two for the multiple testing using gene-based and SNP-based 
approaches. 
Given the large contribution of regulatory variants on complex traits9,10,37, our 
method is likely to identify causal genes. However, we do not claim causality since 
SNPs that contribute to the expression of a gene can also act through other 
mechanisms to determine the phenotype of interest. Replication and experimental 
validations are needed to determine causality. 
 In conclusion, we presented a novel gene-based test, PrediXcan that 
incorporates functional information with regard to gene regulation to identify genes 
associated with disease traits in large GWAS or whole genome sequence datasets. Our 
method has the advantage of providing biological insights into the mechanism, namely 
regulation of gene expression, and direction of effect. This approach can be readily 
applied to existing GWAS datasets through the use of our publically available PredictDB 
resource. We further show the utility of our approach by identifying and replicating a 
number of novel candidate associations within the previously analyzed WTCCC dataset. 
URLs 
PrediXcan software, https://github.com/hakyimlab/PrediXcan 
University of Michigan Imputation-Server, 
https://imputationserver.sph.umich.edu/start.html 
GEUVADIS RNA-Seq data, http://www.geuvadis.org/web/geuvadis/RNAseq-project 
glmnet package, http://www.jstatsoft.org/v33/i01 
International Inflammatory Bowel Disease Genetics Consortium Crohn’s disease meta-
analysis data, http://www.ibdgenetics.org/downloads.html 
Psychiatric Genomics Consortium bipolar disorder data, 
http://www.med.unc.edu/pgc/downloads 
Open Science Data Cloud, 
https://www.opensciencedatacloud.org 
GTEx Portal, http://www.gtexportal.org/ 
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Figure legends 
Figure 1. Mechanism tested by the PrediXcan method. This figure shows the 
conceptual decomposition of the expression level of a gene into three components: 
genetically determined component, a component altered by the trait itself, and the 
remaining factors (including environment). PrediXcan estimates the genetically 
regulated component of expression (GReX) and correlates it with the trait to identify trait-
associated genes. 
Figure 2. PrediXcan framework. The workflow illustrates the steps used in developing 
the PrediXcan method. The top panel shows the data used from the reference 
transcriptome studies: genotype and expression levels (GTEx, GEUVADIS, DGN, etc). 
The sample size of the study is denoted by n, m is the number of genes considered, M 
is the total number of SNPs, and p is the number of available tissues. The second panel 
shows the additive model used to build a database of prediction models, PredictDB. T 
represents the expression trait, and Xk is the number of reference alleles for SNP k. The 
coefficients of the models for each tissue are fitted using the reference transcriptome 
datasets and optimal statistical learning methods chosen among LASSO, Elastic Net, 
OmicKriging, etc. The bottom panel shows the application of PrediXcan to a GWAS 
dataset. Using genetic variation data from the GWAS and weights in PredictDB, we 
“impute” expression levels for the whole transcriptome. These imputed levels are 
correlated with the trait using regression (e.g., linear, logistic, Cox) or non-parametric 
(Spearman) approaches.  (For the disease phenotypes in the WTCCC datasets and the 
replication dataset reported here, we used logistic regression with disease status.) 
Figure 3.  Cross-validated prediction performance vs heritability. This figure shows 
the prediction performance (R2 of GReX vs. observed expression in red) compared to 
gene expression heritability estimates (black with 95% confidence interval in gray). 
Performance was assessed using 10-fold cross-validation in the DGN whole blood 
cohort (n=922) with the elastic net, polygenic score (p < 1x10–4), and using the top SNP 
for prediction. 
Figure 4. Prediction performance of elastic net tested on a separate cohort. Using 
whole blood prediction models trained in DGN, we compared predicted levels of 
expression with observed levels on lymphoblastoid cell lines from the 1000 Genomes 
project. RNA-sequenced data (n=421) on these cell lines have been made publicly 
available by the GEUVADIS consortium. Left panel shows the squared correlation, R2, 
between predicted and observed levels plotted against the null distribution of R2. Right 
panel shows prediction performance (R2 of GReX vs. observed expression in green) 
compared to GEUVADIS gene expression heritability (h2) estimates (black with 95% 
confidence interval in gray).  
Figure 5. Examples of well-predicted genes. These plots show observed vs. 
predicted levels of 4 genes. Predicted levels were computed using whole blood elastic 
net prediction models trained in DGN data. Observed levels were RNA-seq data in 
lymphoblastoid cell lines generated by the GEUVADIS consortium. 
Figure 6. PrediXcan results for type 1 diabetes. Complete results for our analysis of 
type 1 diabetes from the WTCCC using gene expression predicted with the DGN whole 
blood predictors. Panel (a) shows association p-values based on gene position across 
the genome. Panel (b) shows the same results plotted against the null expectation in a 
q-q plot. The red line in panel (b) shows the null expected distribution of p-values. In 
panels (a) and (b), the blue line represents the bonferroni corrected genome-wide 
significance threshold. The top 3 genes are labeled. Panel (c) shows the results of our 
GWAS enrichment analysis. The histogram shows the expected number of genes with a 
p-value < 0.01 based on 10,000 random permutations. The large point shows the 
observed number of previously known T1D genes that fall below this threshold. 
 
Figure 7. Comparison of gene-based methods.  Q-Q plot showing distribution of p-
values derived from each method (VEGAS, SKAT, and PrediXcan) for genes outside of 
the HLA region for Rheumatoid Arthritis.  
 
Table legends 
Table 1. Top PrediXcan results for WTCCC using DGN whole blood prediction 
models. PrediXcan results for bonferroni significant gene associations. To account for 
multiple testing, we used a significance threshold of 5.76x10–6 for all diseases. 
Chromosome and gene start position are based on GENCODE version 12. The cross 
validated prediction R2 between predicted and observed gene expression is based on 
10-fold cross validation within the DGN whole blood sample. 
 
Disea
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ce 
Ch
r TSS 
PrediXc
an Z-
Statisti
c 
PrediXc
an P-
value 
No. of 
SNPs 
in 
Predict
or 
Cross Validated Prediction R2 
RA DCLRE1B V 1 
114,447,
763 -6.68 
2.46E-
11 4 0.0388 
RA PTPN22 G 1 114,356,433 5.67 
1.44E-
08 32 0.0795 
BD PTPRE   10 129,705,325 4.94 
7.71E-
07 38 0.0355 
CD ATG16L1 G 2 
234,118,
697 6.37 
1.94E-
10 20 0.0638 
CD IL23R G 1 67,632,083 5.23 
1.74E-
07 38 0.0378 
CD APEH V 3 49,711,435 5.14 
2.77E-
07 31 0.1164 
CD ZNF300 G ‡ 5 150,273,954 -4.98 
6.29E-
07 34 0.0387 
CD NKD1 G 16 50,582,241 -4.91 
8.91E-
07 43 0.0693 
CD BSN G ‡ 3 49,591,922 -4.68 
2.89E-
06 39 0.2336 
CD GPX1 V 3 49,394,609 -4.62 
3.87E-
06 28 0.0211 
CD SLC22A5 G ‡ 5 
131,705,
444 -4.54 
5.75E-
06 42 0.6356 
HT KCNN4   19 44,270,685 -4.7 
2.62E-
06 81 0.4655 
T1D DCLRE1B V 1 
114,447,
763 -7.84 
4.34E-
15 4 0.0388 
T1D ZNF165 M 6 28,048,753 7.3 
2.92E-
13 19 0.0374 
T1D ERBB3 G 12 56,473,641 -6.81 
1.01E-
11 9 0.2206 
T1D EGFL8 H 6 32,132,360 6.33 
2.52E-
10 36 0.0558 
T1D C6orf136 H 6 
30,614,8
16 -6.33 
2.52E-
10 15 0.0137 
T1D HCG27 H 6 31,165,537 -6.33 
2.52E-
10 81 0.3721 
T1D GTF2H4 H 6 30,875,961 6.33 
2.52E-
10 69 0.0982 
T1D DDR1 H 6 30,844,198 6.33 
2.52E-
10 48 0.1427 
T1D AGER H 6 32,148,745 -6.33 
2.52E-
10 39 0.0502 
T1D POU5F1 H 6 31,130,253 6.33 
2.52E-
10 45 0.2874 
T1D ATP6V1G2 H 6 
31,512,2
39 6.33 
2.52E-
10 95 0.2543 
T1D TUBB H 6 30,687,978 6.33 
2.52E-
10 56 0.0295 
T1D AIF1 H 6 31,582,961 6.33 
2.52E-
10 34 0.039 
T1D CYP21A2 H 6 
32,006,0
42 -6.33 
2.52E-
10 80 0.229 
T1D LSM2 H 6 31,765,173 6.33 
2.52E-
10 31 0.0317 
T1D VARS2 H 6 30,876,019 6.33 
2.52E-
10 87 0.3628 
T1D APOM H 6 31,620,193 -6.33 
2.52E-
10 58 0.0699 
T1D DDAH2 H 6 31,694,815 -6.33 
2.52E-
10 32 0.1943 
T1D NCR3 H 6 31,556,672 -6.33 
2.52E-
10 79 0.2548 
T1D ZSCAN16 M 6 
28,092,3
38 6.16 
7.37E-
10 34 0.0291 
T1D ZKSCAN4 M 6 
28,212,4
01 6.15 
7.73E-
10 17 0.0991 
T1D PTPN22 G 1 114,356,433 5.83 
5.41E-
09 32 0.0795 
T1D RPS26 G ‡ 12 56,435,637 5.82 
6.00E-
09 23 0.0719 
T1D GDF11 V 12 56,137,064 -5.75 
9.11E-
09 39 0.0341 
T1D SUOX G ‡ 12 56,390,964 -5.47 
4.49E-
08 50 0.1339 
T1D BTN3A2 M 6 
26,365,3
87 -5.11 
3.30E-
07 49 0.7662 
T1D PRSS16 M 6 27,215,480 4.83 
1.34E-
06 31 0.1639 
T1D FAM109A V 12 
111,798,
339 -4.76 
1.94E-
06 17 0.0665 
T1D SH2B3 G 12 111,843,752 4.67 
3.05E-
06 26 0.0368 
Evidence: H= HLA-region genes on chromosome 6p21; M=extended Major Histocompatibility 
Complex; G=Genes previously reported to be associated with disease risk in the NHGRI GWAS 
catalog excluding studies with WTCCC samples; G‡= reported in studies including WTCCC 
samples; V= in vicinity of genes of reported gene (1MB). 
 
 
Methods 
Genomic and Transcriptomic Data 
DGN RNA-Seq Dataset 
 We obtained whole blood RNA-Seq38 and genome-wide genotype data for 922 
individuals from the Depression Genes and Networks cohort16, all of European ancestry. 
For our analyses, we used the HCP (hidden covariates with prior) normalized gene-level 
expression data used for the trans-eQTL analysis in Battle et al.16 and downloaded from 
the NIMH repository. Approximately 650K SNPs (minor allele frequency [MAF] > 0.05, 
Hardy-Weinberg Equilibrium [P > 0.05], non-ambiguous strand [no A/T or C/G SNPs]) 
comprised the input set of SNPs for imputation, which was performed on the University 
of Michigan Imputation-Server39,40 with the following parameters: 1000G Phase 1 v3 
ShapeIt2 (no singletons) reference panel, SHAPEIT phasing, and EUR population. Non-
ambiguous strand SNPs with MAF > 0.05, imputation R2 > 0.8 were retained for 
subsequent analysis. To reduce computational burden in the application to WTCCC, we 
used models developed on the HapMap Phase II subset of SNPs. 
GEUVADIS RNA-Seq Dataset 
We obtained freely available RNA-Seq data from 421 lymphoblastoid cell lines 
(LCLs) generated by the GEUVADIS consortium15 and genotype data generated by the 
1000 Genomes project. We used GEUVADIS as a validation dataset to test the gene 
prediction models generated in the DGN cohort.  
GTEx RNA-Seq Datasets 
We used the nine tissues with the largest sample size in the Genotype-Tissue 
Expression (GTEx) Pilot Project14 to test the gene prediction models generated in the 
DGN cohort. Tissue samples included subcutaneous adipose (n=115), tibial artery 
(n=122), left ventricle heart (n=88), lung (n=126), skeletal muscle (n=143), tibial nerve 
(n=98), skin from the sun-exposed portion of the lower leg (n=114), thyroid (n=112), and 
whole blood (n=162). In each tissue, normalized gene expression was adjusted for 
gender, the top 3 principal components (derived from genotype data), and the top 15 
PEER factors (to quantify batch effects and experimental confounders)41. We used 
GTEx to test the portability of predictors developed in whole blood (from the DGN 
cohort) across a wide variety of tissues. 
Additive model for gene expression traits 
 We use an additive genetic model to characterize gene expression traits:   
௚ܻ =  ∑ ݓ௞,௚௞ ܺ௞ + ߳  (1) 
where Yg is the  expression trait of gene g, wk,g is the effect size of marker k for gene g, 
Xk is the number of reference alleles of marker k, and ϵ is the contribution of other 
factors that determine the expression trait assumed to be independent of the genetic 
component. We note that the summation in model (1) is the genetically determined 
component of gene expression (i.e., ܩܴ݁ܺ).  
Effect sizes (wk,g) in model (1) can be estimated using multiple approaches. In 
this paper we compare penalized approaches such as LASSO (Least Absolute 
Shrinkage and Selection Operator)18  and the elastic net19 as well as the more naive 
simple polygenic score estimates. However, other statistical machine learning 
approaches42, such as Random Forest43 or OmicKriging44, can be used within the 
PrediXcan framework to develop prediction models.  
The heritability of gene expression defines an upper bound to how well we can 
predict the trait. We estimated the narrow-sense heritability for each gene using a 
variance component model with a genetic relationship matrix (GRM) estimated from 
genotype data, as implemented in GCTA20. No pair of subjects from the 922 individuals 
in DGN shared genetic relatedness (ߨො) in excess of 5% and thus all were included in the 
narrow-sense heritability estimation. SNPs in the vicinity of each gene (within 1Mb of 
gene start or end, as defined by the GENCODE45 version 12 gene annotation), with 
MAF > 0.05, and in Hardy-Weinberg Equilibrium (P > 0.05) were used to construct the 
GRM for each gene. We calculated the proportion of the variance of gene expression 
explained by these local SNPs using the following mixed-effects model37: 
ܻ = ܾܺ + ܩ௟௢௖௔௟ + ݁ 
ݒܽݎሺܻሻ =  ܣ݈݋݈ܿܽߪ݈݋݈ܿܽ2 + ܫߪ2݁ 
where Y is a gene expression trait and b a vector of fixed effects. Here ܣ௟௢௖௔௟ is the GRM 
calculated from the local SNPs, and (the random effect) ܩ௟௢௖௔௟ denotes the genetic effect 
attributable to the set of local SNPs with var (ܩ௟௢௖௔௟) = ܣ௟௢௖௔௟ߪ௟௢௖௔௟ଶ . In this paper we focus 
on the component of heritability driven by SNPs in the vicinity of each gene since the 
component based on distal SNPs could not be estimated with enough accuracy to make 
meaningful inferences. 
Estimation of the genetic component of gene expression levels (GReX) 
In the simple polygenic score approach, we estimate wk as the single-variant 
coefficient derived from regressing the gene expression trait Y on variant Xk (as 
implemented in the eQTL analysis software Matrix eQTL46) using the reference 
transcriptome data. This yields an estimate, ܩܴ݁෣ܺ , for a GWAS study sample, of the 
(unobserved) genetically determined expression of each gene g:  
ܩܴ݁ ௚ܺ෣ =  ∑ ݓෝ௞,௚௞ ܺ௞  (2) 
In this implementation of polygenic score, we include all SNPs (regardless of 
linkage disequilibrium [LD]) that are associated with the expression level of the gene at 
a chosen p-value threshold in the prediction model. 
In contrast, LASSO uses an L1 penalty as a variable selection method to select a 
sparse set of (uncorrelated) predictors18 while the elastic net linearly combines the L1 
and L2 penalties of LASSO and ridge regression respectively to perform variable 
selection19. We used the R package glmnet to implement LASSO and elastic net with 
⍺=0.5.  
For each gene, LASSO, the elastic net and the simple polygenic score were used 
to provide an estimate of ܩܴ݁ܺ (using equation 2, with the effect size estimates ݓෝ௞,௚௅஺ௌௌை , 
ݓෝ௞,௚ாே and ݓෝ௞,௚௉ௌ , respectively). We included only local SNPs (within 1Mb of the gene start 
or end). In order to determine the optimal modeling method, we compared the 10-fold 
cross-validated prediction R2 (the square of the correlation between predicted and 
observed expression) for the simple polygenic score (ܩܴ݁෣ܺ ௉ௌ) at several p-value 
thresholds (single top SNP, 1x10–4, 0.001, 0.01, 0.05, 0.5, 1) with that from LASSO 
(ܩܴ݁෣ܺ ௅஺ௌௌை) and elastic net (ܩܴ݁෣ܺ ாே).  
We also compared the 10-fold cross-validated prediction R2 from elastic net 
models with different starting SNP sets from the DGN genotype imputation (4.6M 1000 
Genomes Project SNPs (MAF>0.05, R2>0.8, non-ambiguous strand), the 1.9M of these 
SNPs that are also in HapMap Phase II, and the 300K of these SNPs that were 
genotyped in the WTCCC).  
 
Performance of transcriptome prediction in independent cohorts 
We tested the feasibility of predicting the transcriptome (i.e., estimating the 
genetic component of each gene expression trait, ܩܴ݁෣ܺ , in an independent test 
transcriptome dataset) using the elastic net effect sizes trained in the DGN whole blood 
data (n=922). For the test sets, we used independent RNA-Seq datasets from 421 LCL 
cell lines from the 1000 Genomes project generated by the GEUVADIS consortium15 
and the nine tissues from the GTEx pilot project14 (see Supplemental Figure 3). To 
assess performance, we used the square of the Pearson correlation, R2, between 
predicted and observed expression levels.  
PrediXcan in the WTCCC GWAS Datasets  
To illustrate the method, we applied gene prediction models (derived from whole 
blood)  consisting of DGN elastic net predictors to the seven WTCCC disease studies -- 
bipolar disorder (BD), coronary artery disease (CAD), hypertension (HT), type 1 
diabetes (T1D), type 2 diabetes (T2D), Crohn’s disease (CD), and rheumatoid arthritis 
(RA)22 . Genotypes imputed to the 1000G reference sets were used. Imputation was 
done using the University of Michigan Imputation-Server and the same parameters as 
described for the imputation of DGN data. For each disease, cases and controls (1958 
Birth Cohort and the UK Blood Service Cohort) were jointly imputed to avoid subtle 
differences between cases and controls not attributable to disease risk. We excluded all 
SNPs with an imputation R2 < 0.8 and for computational speed we kept only the 
HapMap Phase II subset of SNPs. 
For each WTCCC disease, we estimated ܩܴ݁෣ܺ ாே, and tested it for association 
with disease risk using logistic regression in R (R-project.org). We restricted our 
PrediXcan analysis to include genes with a cross-validated prediction R2 > 0.01 (10% 
correlation) in the DGN sample.  Because the WTCCC studies use shared controls, 
pleiotropy analyses using these datasets would not be straightforward, and comparison 
of results across diseases was avoided. 
GWAS Enrichment analysis 
 Relative to recent association studies, the WTCCC has a small sample size 
(~2,000 cases and ~3,000 controls per disease). Thus, even with our novel method and 
a reduced multiple testing burden, our ability to detect numerous novel gene 
associations may be limited. Alternatively, we tested each disease for an enrichment of 
known disease genes identified from the NHGRI GWAS Catalog25. For each disease, 
we used the reported genes from the GWAS catalog as the set of known disease 
genes. We excluded studies listed in the NHGRI GWAS catalog that included the 
WTCCC samples in order to make sure our known gene lists were independent from 
the current analysis. We then counted the number of known disease genes that had a 
PrediXcan p-value below a given threshold. We compared this to the null expectation 
based on 10,000 randomly drawn gene sets of similar size to the known disease gene 
set to derive an enrichment p-value. We tested enrichment using PrediXcan p-value 
thresholds of 0.05 and 0.01.  
Comparison to large single variant meta-analyses 
 For the top PrediXcan results in the WTCCC, we cross-referenced the SNPs in 
the prediction models for these genes with the publically available single-SNP meta-
analysis summary results. We excluded T1D from this analysis because, to our 
knowledge, there are no publically available meta-analysis studies of this disease. We 
used meta-analyses results for systolic and diastolic blood pressure as a proxy for 
hypertension. For CD, RA, and BD we were able to use meta-analyses for the same 
diseases (CD47, RA48, and BD31). 
Comparison of gene-based tests (PrediXcan, SKAT, VEGAS) 
 We compared the results derived from PrediXcan with those from two widely-
used gene-based tests, namely VEGAS49 and SKAT50,51. VEGAS aggregates 
information from the full set of SNPs within a gene and accounts for LD using 
simulations from the multivariate normal distribution. SKAT is a kernel-based 
association test that evaluates the regression coefficients of the SNPs within a gene by 
a variance component score test in a mixed model framework.  We generated BED-
formatted files for SNPs and genes (as defined by GENCODE v12) and mapped SNPs 
that met post-imputation QC parameters to gene regions using bedtools. The use of an 
offline Perl implementation for VEGAS allowed us to examine the dependence of the 
results from this approach on LD information through the use of the actual genotype 
data (versus the default HapMap CEU reference panel data). We developed an R-
based pipeline that invokes the SKAT package (version 1.0.1) that is publicly available 
from CRAN. We generated a Q-Q plot showing the distribution of gene-level p-values 
for association with RA (for genes outside the HLA region) derived from each gene-
based test to test for systematic departure from the null expectation (of uniform p-
values).  
Replication of PrediXcan findings 
 We selected individuals from Vanderbilt University’s BioVU repository with a 
diagnosis of rheumatoid arthritis48 using a previously validated algorithm for 
identification of RA cases with a reported positive predictive value of 0.94 and sensitivity 
of 0.87, as previously described52. This trained machine learning classifier was applied 
to records with at least one International Classification of Diseases, 9th edition code for 
rheumatoid arthritis to identify true RA cases. RA positive individuals identified by this 
algorithm were genotyped on two platforms: 833 using the Illumina OmniExpress + 
Exome chip and 1408 using the Illumina Omni 2.5 BeadChip.  A total of 2650 samples 
from the Illumina Genotype Control set genotyped on Illumina HumanMap550v1/v3 
were used for controls. We used the following QC thresholds: sample call rate > 0.98, 
SNP call rate > 0.99, MAF > 0.05, HWE p-value > 10–3. Imputation was performed using 
IMPUTE2 with the 1000 Genomes phase 1 v3 European samples as the reference 
panel, phasing was done with SHAPEIT, and SNPs with imputation quality score 
(“INFO”) > 0.50 were retained. To replicate the PrediXcan RA findings that meet 
genome-wide significance, we utilized the DGN whole blood elastic net prediction 
models (as we had done in the discovery WTCCC data). We estimated the genetically 
regulated gene expression level ܩܴ݁෣ܺ ாே in the replication samples and performed 
logistic regression with disease status. 
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